MT-103 (Curacle)

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameMT-103 (Curacle)
Drug Alias NameMT-103
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionTEK receptor tyrosine kinase agonistsAnti-Vascular endothelial growth factorAnti-Angiopoietin-2
TargetsTEK receptor tyrosine kinaseVascular endothelial growth factorAngiopoietin-2
Therapy Area/IndicationsDiabetic macular oedemaWet age-related macular degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCuracle Co LtdMabTics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMabTics Co LtdMemento Medicines IncCuracle Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaWet age-related macular degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A